ARVNArvinas, Inc.

$907M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$79M-40.3% YoY

Gross Profit

$79M100.0% margin

Operating Income

-$402M-511.5% margin

Net Income

-$367M-467.9% margin

EPS (Diluted)

$-6.62

Cash Flow

Operating Cash Flow

-$348M

Free Cash Flow

-$351M

Stock-Based Comp.

$72M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$645M

Stockholders' Equity

$660M

Cash & Equivalents

$312M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$79M	$131M	-40.3%
Gross Profit	$79M	$131M	-40.3%
Operating Income	-$402M	-$263M	-52.5%
Net Income	-$367M	-$283M	-30.0%

ARVN FY 2023 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena